Now trading at a price of $50.84, Series has moved -1.3% so far today.
Series returned gains of 20.8% last year, with its stock price reaching a high of $61.7 and a low of $35.45. Over the same period, the stock underperformed the S&P 500 index by -6.4%. The company's 50-day average price was $53.43. GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. Based in London, United Kingdom, the Large-Cap Health Care company has 66,841 full time employees. Series has offered a 1.3% dividend yield over the last 12 months.
Wider Gross Margins Than the Industry Average of 57.85%:
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue (M) | $24,354 | $24,696 | $29,324 | $30,328 | $31,376 | $32,667 |
| Gross Margins | 67% | 67% | 67% | 72% | 71% | 72% |
| Net Margins | 26% | 21% | 53% | 18% | 9% | 19% |
| Net Income (M) | $6,388 | $5,096 | $15,621 | $5,308 | $2,951 | $6,289 |
| Diluted Shares (M) | 5,385 | 5,387 | 4,311 | 4,312 | 4,314 | 4,315 |
| Earnings Per Share | $1.43 | $1.08 | $3.66 | $1.2 | $0.62 | $1.39 |
| EPS Growth | n/a | -24.48% | 238.89% | -67.21% | -48.33% | 124.19% |
| Free Cash Flow (M) | $8,441 | $7,952 | $7,403 | $6,768 | $6,554 | $7,741 |
| Total Debt (M) | $23,425 | $20,572 | $17,035 | $15,205 | $14,637 | $14,708 |
| Net Debt / EBITDA | 2.13 | 2.52 | 1.55 | 1.36 | 1.64 | 1.1 |
| Current Ratio | 0.91 | 0.79 | 0.91 | 0.88 | 0.78 | 0.82 |
an Increase in Expected Earnings Improves Its Value Outlook but Priced at a Premium:
Series has a trailing twelve month P/E ratio of 14.0, compared to an average of 22.94 for the Health Care sector. Based on its EPS guidance of $5.23, the company has a forward P/E ratio of 10.2. According to the 20.4% compound average growth rate of Series's historical and projected earnings per share, the company's PEG ratio is 0.69. Taking the weighted average of the company's EPS CAGR and the broader market's 5-year projected EPS growth rate, we obtain a normalized growth rate of 13.8%. On this basis, the company's PEG ratio is 1.01. This implies that the shares are fairly valued. In contrast, Series is likely overvalued compared to the book value of its equity, since its P/B ratio of 4.26 is higher than the sector average of 3.19. The company's shares are currently trading 373.0% below their Graham number.
Analysts Give Series an Average Rating of Hold:
The 8 analysts following Series have set target prices ranging from $47.0 to $70.0 per share, for an average of $57.94 with a hold rating.
Series has a very low short interest because 0.7% of the company's shares are sold short. Institutions own 18.8% of the company's shares, and the insider ownership rate stands at 0.06%, suggesting a small amount of insider investors. The largest shareholder is FMR, LLC, whose 3% stake in the company is worth $3,440,256,473.
